Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medsenic Partners With Phebra for the Clinical Development of the Oral Form of Arscimed\u00ae for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Receives Notice of Approval for a New US Patent Broadening the Use of Arsenic Trioxide to Treat the Relapsing-Remitting Form of Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Receives Positive Pre-IND Response from FDA to Initiate a Phase III Clinical Study in cGvHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Publishes an Article in Transplantation and Cellular Therapy, Unveiling High Response Rate and Corticosteroid Sparing With Arsenic Trioxide-based First-line Therapy in cGvHD after allo-HSCT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Medsenic","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Bone Therapeutics to Broaden and Derisk Therapeutic Portfolio by Acquiring Majority Participation in Medsenic","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Medsenic","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics to Start a New Euronext Equity Story with A Change of Name to Bio Senic, Following the Acquisition of A Majority Participation of Medsenic Valued at EUR 40 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosenic Provides Update Regarding Current License Agreement With Phebra","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Medsenic

    Menu

    Medsenic

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Medsenic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biosenic Provides Update Regarding Current License Agreement With Phebra

              Details:

              Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.

              Lead Product(s): Arsenic Trioxide

              Therapeutic Area: Immunology Product Name: OATO

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Phebra

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement May 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Medsenic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bone Therapeutics to Start a New Euronext Equity Story with A Change of Name to Bio Senic, Following the Acquisition of A Majority Participation of Medsenic Valued at EUR 4...

              Details:

              The acquisition of Medsenic and its specialized pipeline in the development of optimized formulations of arsenic trioxide (Arscimed) and their applications in serious inflammatory/autoimmune conditions and other potential new indications.

              Lead Product(s): Arsenic Trioxide

              Therapeutic Area: Immunology Product Name: Arscimed

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Bone Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition October 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Medsenic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bone Therapeutics to Broaden and Derisk Therapeutic Portfolio by Acquiring Majority Participation in Medsenic

              Details:

              Bone Therapeutics would also issue and automatically allot one subscription right to each outstanding share of Bone Therapeutics, in case of statistically positive interim results of the ALLOB Phase IIb trial.

              Lead Product(s): Allogeneic Bone Cell Therapy

              Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Bone Therapeutics

              Deal Size: $5.0 million Upfront Cash: $5.0 million

              Deal Type: Acquisition August 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Medsenic

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Medsenic Publishes an Article in Transplantation and Cellular Therapy, Unveiling High Response Rate and Corticosteroid Sparing With Arsenic Trioxide-based First-line Therap...

              Details:

              First-line combination of Arscimed (arsenic trioxide) and prednisone in cGvHD showed an Overall Response Rate (ORR) at 6 months of 75%, allowing rapid corticosteroid tapering.

              Lead Product(s): Arsenic Trioxide

              Therapeutic Area: Immunology Product Name: Arscimed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Medsenic

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Medsenic Receives Positive Pre-IND Response from FDA to Initiate a Phase III Clinical Study in cGvHD

              Details:

              The primary endpoint of this prospective, multicenter, non-randomized study was the improvement of treatment response with Arscimed® (arsenic trioxide) in combination with prednisone, with or without cyclosporine.

              Lead Product(s): Arsenic Trioxide,Prednisone,Cyclosporine

              Therapeutic Area: Immunology Product Name: Arscimed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Medsenic

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Medsenic Receives Notice of Approval for a New US Patent Broadening the Use of Arsenic Trioxide to Treat the Relapsing-Remitting Form of Multiple Sclerosis

              Details:

              Arsenic trioxide has the unique property of increasing cellular oxidative stress to the point where it induces cell death of activated cells (enhanced apoptosis). It also has an effect on pro-inflammatory cytokines.

              Lead Product(s): Arsenic Trioxide

              Therapeutic Area: Immunology Product Name: Arscimed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Medsenic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Medsenic Partners With Phebra for the Clinical Development of the Oral Form of Arscimed® for the Treatment of Autoimmune Diseases

              Details:

              Exclusive licensing agreement for the development of a patented formulation of oral arsenic trioxide in the treatment of autoimmune diseases. Initially the oral formulation of arsenic trioxide will target the treatment of patients with chronic graft-versus-host disease.

              Lead Product(s): Arsenic Trioxide

              Therapeutic Area: Immunology Product Name: Arscimed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Phebra

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership June 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY